Replies to post #85764 on Biotech Values

[DewDiligence]

Teva has annual sales of about $14B. If Teva’s Lovenox ANDA has been re-characterized as a 505b2 NDA, this in itself would not meet (or even come close to) the materiality threshold requiring Teva to disclose it to investors.